Biopharma Dealmaking
How the Year’s Top Licensing and M&A Transactions Are Changing the Industry Landscape

Sign me up

What is the webinar about?

As external innovation continues to be a critical part of portfolio strategy for the biggest BioPharma players, it drives the deals activity as companies race to license and acquire the assets that will give them market segment dominance. All indications are that 2018 will another mega-dealmaking year as big dollars have flowed forth for licensing and M&A deals in the first half of the year. Using Cortellis tools, our experts delve into these partnerships and M&As to provide attendees with valuable market insights:

  • Who has emerged early in the year as the biggest dealmakers
  • A breakdown of the top 3 biopharma licensing deals and the top 3 M&A deals
  • What therapeutic areas stand out, and why
  • A closer examination of the burgeoning Asia Pacific region where dealmakers are more active than ever
  • Preview of the biggest deals and outlook for Q3

Expert Speakers

Paul D'Souza, Pharmaceutical Industry Analyst at Clarivate Analytics

 
  • Paul has 11 years experience supporting pharmaceutical and consultancy clients through analyses of pharmaceutical drugs, M&A and licensing deals data, particularly Cortellis CDI
  • Paul currently analyses quarterly trends in pharmaceutical M&A and licensing activity

Donald Johnston, Senior Marketing Communication Director at Clarivate Analytics

 
  • Donald is senior marketing communication director at Clarivate Analytics
  • Don has worked with Clarivate’s Life Sciences solutions, particularly the BioWorld and BioWorld MedTech news services, for more than two decades

Event details

  • Date October 03, 2018
  • Time 10 AM EDT/ 3 PM BST

Who should attend

  • Professionals in business development and licensing, mergers and acquisitions
  • Marketing strategy professionals
  • Biopharma financial sector
  • Anyone with a need for monitoring the Biopharma deals landscape

What you will learn

After you attend this webinar, you will have learned this key information on BioPharma deals in the first half of 2018:

  • Details on the top 3 global BioPharma licensing deals
  • Specifics for the top 3 global BioPharma mergers/acquisitions
 
  • The key licensing and M&A deals in the Asia Pacific (APAC) region
  • Dealmaking in APAC broken down by country

+